Results 301 to 310 of about 189,595 (350)
Some of the next articles are maybe not open access.
Anticoagulation Therapy in Children
Seminars in Thrombosis and Hemostasis, 2003Thromboembolic events (TEs) in children are rare but are becoming a recognized cause of morbidity and mortality, particularly in children with serious underlying primary conditions such as congenital heart disease, cancer, or prematurity. Neonates, infants, and adolescents are most at risk for developing TEs among children, and the presence of a ...
Anthony K.C. Chan, Shoshana Revel-Vilk
openaire +6 more sources
Anticoagulant therapy with ancrod
Critical Reviews in Oncology/Hematology, 19935.7. 5.8 ......... . . Treatment of venous thromboembolism 5.1.1. Deep venous thrombosis 5.1.2. Pulmonaryembolus Prophylaxis of venous thromboembolism Other venous thrombotic disorders Treatment of arterial thromboembolism 5.4.
Jeffrey S. Ginsberg, R.L. Soutar
openaire +3 more sources
Anticoagulation clinics and the monitoring of anticoagulant therapy
International Journal of Cardiology, 1988Patients attending an anticoagulation clinic were studied to delineate predisposing risk factors for bleeding and thromboembolic episodes. Seventy-three patients were observed for a total of 921.8 patient-treatment months. The mean duration of treatment was 12.6 months (range 3-36 months).
Richard Charney +3 more
openaire +3 more sources
Indications for Anticoagulant Therapy
New England Journal of Medicine, 1963THE place of anticoagulant therapy in the various types and phases of occlusive vascular disease, venous and arterial, has been debated ever since its introduction into clinical practice more than fifteen years ago. The widely divergent opinions and seemingly conflicting results of therapeutic trials that have appeared are unmistakable symptoms of ...
openaire +4 more sources
Pharmacologic Therapies in Anticoagulation
Medical Clinics of North America, 2016Anticoagulants are beneficial for prevention and treatment of venous thromboembolism and stroke prevention in atrial fibrillation. The development of target-specific oral anticoagulants is changing the landscape of anticoagulation therapy and created growing interest on this subject.
Joyce E. Wipf, Joana Lima Ferreira
openaire +3 more sources
Anticoagulant therapy in practice
Orvosi Hetilap, 2012Atrial fibrillation is a risk factor for ischemic stroke. To prevent stroke oral anticoagulants can be administered. Old and new types of anticoagulants are available. Nowadays, old type, acenocumarol based anticoagulants are used preferentially in Hungary.
Csilla Vér +2 more
openaire +3 more sources
Anticoagulant therapy in pregnancy
European Journal of Obstetrics & Gynecology and Reproductive Biology, 1999Anticoagulation during pregnancy should derive benefit from recent advances in anticoagulant therapy. Unfractionated heparin is at present the drug of choice for most of the indications of thromboprophylaxis as well as for acute venous thrombosis during pregnancy but it is likely that, in the near future, low molecular weight heparins will supercede ...
Fabrice Lecuru +4 more
openaire +3 more sources
Indications for anticoagulant therapy
American Heart Journal, 1969Abstract The value of anticoagulant therapy is solidly established in the presence of deepvein thrombosis and pulmonary embolism, in the presence of recurrent cerebral ischemic episodes when reparative vascular surgery is not possible, and in postoperative and bedridden patients, at least those with a high risk of pulmonary embolism.
Alan F. Lyon, Arthur C. DeGraff
openaire +3 more sources
Anticoagulant Therapy—1974 [PDF]
JAMA: The Journal of the American Medical Association, 1974 THE national impact of thrombosis should not be underestimated. Arterial thromboembolism is a major, if not the primary, contributor to the number 1 (acute myocardial infarction), number 3 (stroke), and the number 4 (renal) causes of death in the United States.
openaire +2 more sources
Advances in anticoagulation therapy
JAAPA, 2018ABSTRACT Because atrial fibrillation (AF) is a major risk for thrombotic disease, many patients with AF are managed with anticoagulation for primary or secondary prevention of these events. The emergence of novel oral anticoagulants offers patients and providers options to consider beyond warfarin.
Michael Gil, Emily Webster
openaire +3 more sources